Collegium Pharmaceutical, Inc.
COLLHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Collegium Pharmaceutical, Inc. (COLL) is listed under Drug Manufacturers - Specialty & Generic. Valued at $747.5M, COLL is a small-cap name in its sector. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Market Cap
$747.5M
Beta
0.73
P/E (TTM)
18.52
P/E (Fwd)
3.16
EPS (TTM)
$1.24
EPS (Fwd)
$7.26
ROE
17.6%
ROA
5.8%
Cash
$129.5M
Total Debt
$1.22B
Free CF
$324.0M
52W Change
-35.0%
Annual Financials
Cash vs Debt
Where COLL stands vs its 150-day and 200-day moving averages
As of the September 24, 2026 close, COLL finished 32.26% below its 150-day moving average ($33.14) and 38.76% below its 200-day moving average ($36.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COLL overbought or oversold?
At the September 24, 2026 close, COLL's RSI(14) was 28.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Collegium Pharmaceutical, Inc. carries $1.22B in total debt against $129.5M in cash reserves — debt is roughly 9.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $324.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 17.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $463.9M (2022) to $780.6M (2025), reflecting a 68% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Collegium Pharmaceutical, Inc. and its sector.